Sunday, 20 September 2026European Markets

INTEXA Stock Impressive Fall 16% So Far On Thursday, Underperforms Market

Loading stream...

(vianews) - shares of intexa (cac 40: itxt.pa) dropped by a staggering 16.44% to €2.44 at 13:58 est on thursday, after five sequential sessions in a row of losses. cac 40 is dropping 0.48% to €7,289.82, after two sequential sessions in a row of losses. this seems, at the moment, a somewhat bearish trend exchanging session today.

about intexa

intexa s.a. engages in the operation of the photovoltaic installation in saint-andré-de-cubzac, france. the company was founded in 2011 and is headquartered in saint-etienne, france. intexa s.a. is a subsidiary of casino guichard-perrachon.

earnings per share

as for profitability, intexa has a trailing twelve months eps of €0.1.

pe ratio

intexa has a trailing twelve months price to earnings ratio of 24.4. meaning, the purchaser of the share is investing €24.4 for every euro of annual earnings.

volume

today's last reported volume for intexa is 2 which is 75% below its average volume of 8.

more news about intexa (itxt.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com